Roche is set to pay out $750 million upfront to acquire digital pathology specialist Path AI in a move by the pharma giant to accelerate the use of artificial intelligence in diagnostic algorithms. The deal, which is expected to close in the second half of this year, will see Roche make an upfront payment of $750 million for PathAI, plus additional payments of up to $300 million linked to milestone achievements. Once the deal is locked in, PathAI will be merged into Roche’s Diagnostics division, the companies said in a May 7 release. The transaction will give Roche access to PathAI’s Image Management System, or IMS, a user-friendly software interface that weds analysis and workflow capabilities within the digital pathology lab. Roche says it now intends to scale the platform “globally.”

Full report : Swiss pharmaceutical group Roche agrees to acquire US-based AI diagnostics tool developer PathAI for up to $1.05 billion, paying $750 million upfront, set to close in H2 2026.